Today, I'm gonna talk about Teprotumumab.

今天，我要谈谈Teprotumumab

It's a tough name, but it's a drug that is being currently trialed for thyroid eye disease and been found to be very effective in reducing the bulging, double vision, and improving the quality of life of patients afflicted with this disease.

这是一个很难的名字，但它是一种药物，目前正在用来试验甲状腺眼病，并被发现在减少眼肿、双重视力、及改善患者的生活质量方面非常有效。

Briefly, I just wanted to talk about how it works, so that people can think about it and potentially enroll in the next trial, which will be coming up in Los Angeles, in addition to several other sites in the US.

简而言之，我只是想谈谈它是如何运作的，这样人们就可以考虑考虑它，它就有可能参加下一个试验，这个试验将在洛杉矶进行，还有美国的其他几个试验点。

So, Graves' disease often affects the eyes.

所以，格雷夫斯病通常会影响到眼睛

The immune system, here in these little green cells, are often provoked by the thyroid receptors, or the TSIs that people talk about, and these antibodies bind to the immune cells and cause them to attack the eyes, and what happens is that the eyes bulge out, because they accumulate scar tissue behind them and in the muscles, and it causes a whole host of problems that people have, including double vision.

免疫系统,在这里是这些绿色的小细胞,常常引起甲状腺受体,或人们讨论的TSI,和那些抗体结合的免疫细胞,导致他们攻击眼睛,然后会发生眼睛肿胀,因为眼底会积累疤痕组织和肌肉,这导致许多人出现各种症状，包括复视。

Well, Teprotumumab is an antibody itself, but it's an antibody that's, and that's a little sign for an antibody, to the insulin-like growth factor 1 receptor, and that's really a tough name, but we just refer to it as IGF-1.

Teprotumumab本身就是一种抗体，但这是一种抗体的对于胰岛素生长因子1受体来说的一个小标记，这真是个难听的名字，但我们把它叫做IGF-1

The idea is that this antibody binds to the same receptor, but what it doesn't do is, it doesn't activate the immune cell, in fact, it keeps it in a nice quiet state.

这个想法就是这个抗体和同一个受体结合，但是它没有做的是，它没有激活免疫细胞，事实上，它保持了一个很好的安静的状态

So it doesn't destroy your immune system, it just allows your immune system not to become activated by the bad antibodies and the other things that activate it.

所以它不会破坏你的免疫系统，它只是让你的免疫系统不被不良的抗体或其他能够激活它的东西激活。

And what we've found is that, when you add Teprotumumab, or you give patients Teprotumumab, you have a decrease in the eye bulging, you have a decrease in the double vision, and you have a much higher quality of life, because people resume their normal appearance, and they also can resume their daily activities. So, watch out more for Teprotumumab.

我们发现,当你添加Teprotumumab抗体,或者你给患者Teprotumumab抗体,你的眼睛肿胀会变轻,复视的问题缓解,并且你会有一个更高的生活质量,因为人们一旦恢复正常的外观,他们就可以恢复日常活动。所以，应当多注意Teprotumumab相关问题。

We'll begin the trial in Los Angeles for patients who are newly diagnosed within nine months of thyroid eye disease, and hopefully, very soon, it will be available to everyone.

我们将在洛杉矶对那些在九个月内被新诊断出来的甲状腺眼病患者进行试验，希望，很快，每个人都能使用此治疗方式。